184 related articles for article (PubMed ID: 33411033)
1. Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy.
Fujita K; Motoyama S; Sato Y; Wakita A; Nagaki Y; Minamiya Y; Miura M
Med Oncol; 2021 Jan; 38(1):6. PubMed ID: 33411033
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
3. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
4. Association between ABCC2 polymorphism and hematological toxicity in patients with esophageal cancer receiving platinum plus 5-fluorouracil therapy.
Fujita K; Motoyama S; Sato Y; Wakita A; Nagaki Y; Minamiya Y; Miura M
Esophagus; 2022 Jan; 19(1):146-152. PubMed ID: 34347217
[TBL] [Abstract][Full Text] [Related]
5. Homozygous GNAS 393C-allele carriers with locally advanced esophageal cancer fail to benefit from platinum-based preoperative chemoradiotherapy.
Alakus H; Bollschweiler E; Hölscher AH; Warnecke-Eberz U; Frazer KA; Harismendy O; Lowy AM; Mönig SP; Eberz PM; Maus M; Drebber U; Siffert W; Metzger R
Ann Surg Oncol; 2014 Dec; 21(13):4375-82. PubMed ID: 24986238
[TBL] [Abstract][Full Text] [Related]
6. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma.
Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J
Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
[TBL] [Abstract][Full Text] [Related]
8. Cuproptosis-Related Gene -
Yun Y; Wang Y; Yang E; Jing X
Pharmgenomics Pers Med; 2022; 15():733-742. PubMed ID: 35923305
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
10. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
[TBL] [Abstract][Full Text] [Related]
12. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.
Li T; Peng J; Zeng F; Zhang K; Liu J; Li X; Ouyang Q; Wang G; Wang L; Liu Z; Liu Y
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):774-780. PubMed ID: 28737129
[TBL] [Abstract][Full Text] [Related]
13. TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Omatsu H; Kuwahara A; Yamamori M; Fujita M; Okuno T; Miki I; Tamura T; Nishiguchi K; Okamura N; Nakamura T; Azuma T; Hirano T; Ozawa K; Hirai M
Int J Med Sci; 2013; 10(12):1755-60. PubMed ID: 24151445
[TBL] [Abstract][Full Text] [Related]
14. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
15. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
Chen J; Yin W; Yao H; Gu W
Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
[TBL] [Abstract][Full Text] [Related]
16. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010.
Liu S; Wen J; Yang H; Li Q; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Zhao L; Liu H; Hu Y; Liu M; Fu J; Xi M
Eur J Cancer; 2020 Oct; 138():113-121. PubMed ID: 32877795
[TBL] [Abstract][Full Text] [Related]
17. Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma.
Kato K; Ito Y; Nozaki I; Daiko H; Kojima T; Yano M; Ueno M; Nakagawa S; Takagi M; Tsunoda S; Abe T; Nakamura T; Okada M; Toh Y; Shibuya Y; Yamamoto S; Katayama H; Nakamura K; Kitagawa Y;
Gastroenterology; 2021 Dec; 161(6):1878-1886.e2. PubMed ID: 34389340
[TBL] [Abstract][Full Text] [Related]
18. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
[TBL] [Abstract][Full Text] [Related]
19. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
[TBL] [Abstract][Full Text] [Related]
20. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
